Recent research is shedding new light on the potential of psychedelics to treat alcohol use disorder (AUD), offering hope for millions struggling with alcoholism. Two new studies, including one with contributions from a top federal drug official, have demonstrated promising results in using substances like psilocybin to reduce alcohol consumption and cravings.

Study 1: Psilocybin’s Impact on Alcohol Use Disorder

A groundbreaking study, co-authored by National Institute on Drug Abuse (NIDA) Director Nora Volkow, explored the effects of a single dose of psilocybin on individuals with severe AUD. The results were striking:

1. Significant Decrease in Alcohol Consumption: Participants showed a marked reduction in alcohol intake over a 12-week period following a single 25mg dose of psilocybin.
2. Reduced Cravings: Alcohol cravings decreased immediately and remained lower for up to 12 weeks post-treatment.
3. Increased Self-Efficacy: Participants reported greater confidence in their ability to abstain from alcohol, an effect that persisted throughout the study period.
4. Lasting Effects: At the 4-week mark, 9 out of 10 participants significantly reduced their daily drink intake. By week 12, 7 out of 10 still maintained this reduction.

Study 2: Classic Psychedelics and Addiction Treatment

A separate study published in Progress in Neuro-Psychopharmacology and Biological Psychiatry analyzed previous research on classic psychedelics like psilocybin and LSD. The findings suggest:

1. Potential for Treating Drug Addiction: Classic psychedelics showed promise in treating various substance use disorders, with a particular emphasis on AUD.
2. Neuroplasticity Modulation: These substances appear to work by modulating neuroplasticity in the brain.
3. Low Risk of Dependence: Unlike many traditional treatments, serotonergic psychedelics do not produce physical dependence or withdrawal symptoms.

Implications and Future Research

While these studies offer exciting possibilities, researchers caution that more extensive, placebo-controlled trials are necessary to establish firm conclusions. Some key points to consider:

• Variability in Effects: The duration and intensity of benefits can vary significantly between individuals.
• Need for Further Research: Studies using different doses and protocols are required to enhance the evidence base.
• Potential Bias: High expectations due to positive media coverage may influence outcomes to some degree.

As research progresses, the potential of psychedelics in treating addiction continues to grow. From psilocybin for alcoholism to CBD for various substance use disorders, these studies are opening new avenues for treatment.